Innoviva reports profitable Q1 2026 results
Innoviva, Inc. reported a profitable first quarter of 2026, with total revenue of $97,994 thousand and net income of $186,595 thousand.
Rhea-AI Filing Summary
Innoviva, Inc. reported a profitable first quarter of 2026, with total revenue of $97,994 thousand and net income of $186,595 thousand. Diluted earnings per share were $2.22, compared with a diluted net loss per share of $0.74 a year earlier.
Royalty revenue, net, was $55,167 thousand, while net product sales rose to $41,371 thousand. Management highlighted Innoviva Specialty Therapeutics, noting IST net product sales growth of 37% year over year, including 29% growth in U.S. sales.
Results were boosted by changes in fair values of equity method investments of $157,650 thousand and equity and long-term investments of $33,575 thousand. Cash and cash equivalents increased to $603,085 thousand as of March 31, 2026, supported by positive operating and investing cash flows.
Positive
- Sharp profitability improvement: Net income reached $186,595 thousand in Q1 2026 versus a net loss of $46,584 thousand a year earlier, reflecting strong investment gains alongside solid royalty and product revenues.
- Strong balance sheet and liquidity: Cash and cash equivalents rose to $603,085 thousand and equity method and other long-term investments to $764,454 thousand, supporting ongoing capital deployment, including activity under the $125 million share repurchase program.
Negative
- None.
Insights
Innoviva swung from a prior loss to strong Q1 2026 profitability, driven largely by investment gains and growing product sales.
For Q1 2026, Innoviva generated total revenue of $97,994 thousand and income from operations of $38,154 thousand. The largest driver of bottom-line strength was non-operating items: changes in fair values of equity method investments contributed $157,650 thousand, and equity and long-term investments added another $33,575 thousand.
Core operations remained solid, with royalty revenue, net, at $55,167 thousand and net product sales of $41,371 thousand. Management emphasized Innoviva Specialty Therapeutics, citing 37% year-over-year net product sales growth, including 29% growth in U.S. sales, indicating expanding commercial traction for the critical care and infectious disease portfolio.
Liquidity strengthened, as cash and cash equivalents rose to $603,085 thousand at March 31, 2026, supported by net cash provided by operating activities of $35,282 thousand and net cash provided by investing activities of $37,008 thousand. The company continues to carry convertible senior notes due 2028 of $258,095 thousand, but the combination of substantial cash, investment portfolio value, and durable royalty inflows provides significant financial flexibility for capital deployment and share repurchases described by management.
8-K Event Classification
Key Figures
Key Terms
royalty revenue, net financial
net product sales financial
equity method investments financial
convertible senior notes financial
forward-looking statements regulatory
Offering Details
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How did Innoviva (INVA) perform financially in Q1 2026?
What were Innoviva’s main revenue sources in the first quarter of 2026?
How fast are Innoviva Specialty Therapeutics (IST) sales growing?
What drove Innoviva’s large increase in Q1 2026 net income?
What is Innoviva’s cash position as of March 31, 2026?
How leveraged is Innoviva following its Q1 2026 results?
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact Name of Registrant as Specified in its Charter)
| (State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification Number) |
(
(Addresses, including zip code, and telephone numbers, including area code, of principal executive offices)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition
On May 6, 2026, Innoviva, Inc. (the “Company”) issued a press release regarding its results of operations and financial condition for the quarter ended March 31, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report.
The information in Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits
(d) Exhibits
| 99.1 | Press Release dated May 6, 2026 | |
| 104 | Cover Page Interactive File (the cover page tags are embedded within the Inline XBRL document) | |
-2-
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| INNOVIVA, INC. | ||||||
| Date: May 6, 2026 | By: | /s/ Pavel Raifeld | ||||
| Pavel Raifeld | ||||||
| Chief Executive Officer | ||||||
-3-
Exhibit 99.1
Innoviva Reports First Quarter 2026 Financial Results; Highlights Recent Company Progress
Generated $58.6 million in revenue from resilient royalties portfolio
Achieved IST U.S. net product sales of $34.2 million for the first quarter, representing 29% year-over-year growth
Significant value created across strategic healthcare asset portfolio
BURLINGAME, Calif. – May 6, 2026 – Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified biopharmaceutical company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (“IST”), and a portfolio of strategic investments in healthcare assets, today reported financial results for the first quarter ended March 31, 2026, and highlighted select corporate progress and achievements.
“We delivered a strong start to 2026, driven by the resilience of our royalty portfolio, continued excellent commercial progress at IST, and meaningful value creation across our strategic healthcare assets,” said Pavel Raifeld, Chief Executive Officer of Innoviva. “IST achieved 37% year-over-year net product sales growth in the first quarter of 2026, including 29% growth in U.S. sales.”
“We also remained active in executing our capital allocation priorities, including increased activity under our $125 million share repurchase program, underscoring our confidence in Innoviva’s long-term value proposition. Innoviva’s strong track record across its operating and strategic healthcare assets, coupled with significant cash resources and durable royalty inflows, positions us well for accretive capital deployment and long-term shareholder value creation throughout variable market environments,” concluded Mr. Raifeld.
Financial Highlights for the First Quarter of 2026
| • | Total revenue: $98.0 million, yielding 11% growth compared to $88.6 million for the first quarter 2025. |
| • | Royalty revenue: gross royalty revenue from Glaxo Group Limited (“GSK”) was $58.6 million, compared to $61.3 million for the first quarter 2025. |
| • | Net product sales: $41.4 million ($34.2 million U.S. and $7.2 million ex-US), representing 37% growth compared to $30.3 million in the same quarter of 2025. U.S. net product sales primarily consisted of $19.7 million from GIAPREZA®, $11.6 million from XACDURO®, and $2.5 million from XERAVA®. |
| • | Income from operations: $38.2 million, compared to $41.4 million for the first quarter 2025, reflecting continued investment in commercial activities, as well as product and business development. |
| • | Equity and long-term investments: net favorable changes in fair value of equity and long-term investments totaled $191.2 million, primarily attributable to share price appreciation of Armata Pharmaceuticals. Innoviva’s strategic healthcare investments were valued at $773.3 million as of March 31, 2026, and consisted of $603.4 million in Armata Pharmaceuticals, $138.2 million in other strategic equity and convertible debt, and $31.7 million held by ISP Fund. |
| • | Net income: $186.6 million ($2.52 basic earnings per share) was driven primarily by higher revenue and the positive impact of changes in the fair values of equity and long-term investments. |
| • | Cash and cash equivalents: Totaled $603.1 million. Royalty and net product sales receivables totaled $92.6 million as of March 31, 2026. |
Key Business and R&D Highlights
| • | NUZOLVENCE® (zoliflodacin): a first-in-class, single-dose oral medication for the treatment of uncomplicated urogenital gonorrhea due to Neisseria gonorrhoeae in adults and pediatric patients 12 years and older weighing at least 35kg, developed in partnership with The Global Antibiotic Research & Development Partnership (“GARDP”). |
| • | In December 2025, IST received U.S. Food and Drug Administration (FDA) approval of NUZOLVENCE®, one of the first new treatments approved by the FDA for uncomplicated urogenital gonorrhea in nearly two decades. |
| • | The Company remains on track to make NUZOLVENCE® available to patients in the second half of 2026. |
| • | Strategic healthcare assets |
| • | Innoviva’s strategic healthcare asset portfolio experienced meaningful growth this quarter, including notable value crystallization at Armata Pharmaceuticals. Innoviva remains focused on disciplined capital deployment across healthcare opportunities where it believes its strategic perspective and operating experience can support long-term sustained returns. |
| • | Capital Allocation |
| • | During the first quarter of 2026, Innoviva repurchased 971,066 shares for $20.4 million under its $125 million share repurchase program. Since inception, and through the end of this quarter, the Company has repurchased 1,198,921 shares for $25.0 million, reflecting the Company’s continued confidence in its intrinsic value and long-term outlook. |
About Innoviva
Innoviva is a diversified biopharmaceutical company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (“IST”), and a portfolio of strategic investments in healthcare assets. Innoviva’s royalty portfolio includes respiratory assets partnered with Glaxo Group Limited (“GSK”). Innoviva is entitled to receive royalties from GSK on sales of RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®. Innoviva’s critical care and infectious disease assets under the IST platform include GIAPREZA® (angiotensin II) for increasing blood pressure in adults with septic or other distributive shock, XACDURO® (sulbactam for injection; durlobactam for injection), co-packaged for intravenous use for the treatment of adults with hospital-acquired and ventilator-associated bacterial pneumonia caused by susceptible strains of Acinetobacter baumannii-calcoaceticus, XERAVA® (eravacycline) for the treatment of complicated intra-abdominal infections in adults, ZEVTERA
- 2 -
(ceftobiprole), an advanced-generation cephalosporin antibiotic licensed from Basilea Pharmaceutica International Ltd, Allschwil, and NUZOLVENCE® (zoliflodacin), approved by the FDA for the oral treatment of uncomplicated urogenital gonorrhea in adults and pediatric patients 12 years of age and older weighing at least 35 kg. For more information about Innoviva, go to www.inva.com. For information about Innoviva Specialty Therapeutics, go to www.innovivaspecialtytherapeutics.com.
ANORO®, RELVAR® and BREO® are trademarks of the GSK group of companies. ZEVTERA is a trademark of Basilea Pharmaceutica Ltd, Allschwil.
Forward Looking Statements
This press release contains certain “forward-looking” statements as that term is defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things, statements relating to goals, plans, objectives, and future events. Innoviva intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. The words “anticipate”, “expect”, “goal”, “intend”, “objective”, “opportunity”, “plan”, “potential”, “target” and similar expressions are intended to identify such forward-looking statements. Such forward-looking statements involve substantial risks, uncertainties, and assumptions. These statements are based on the current estimates and assumptions of the management of Innoviva as of the date of this press release and are subject to known and unknown risks, uncertainties, changes in circumstances, assumptions and other factors that may cause the actual results of Innoviva to be materially different from those reflected in the forward-looking statements. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, among others, risks related to: expected cost savings; lower than expected future royalty revenue from respiratory products partnered with GSK; the commercialization of RELVAR®/BREO® ELLIPTA®, ANORO® ELLIPTA®, GIAPREZA®, XERAVA®, XACDURO®, ZEVTERA® and NUZOLVENCE® in the jurisdictions in which these products have been approved; the strategies, plans and objectives of Innoviva (including Innoviva’s growth strategy and corporate development initiatives); the timing, manner, and amount of potential capital returns to shareholders; the development of the LYNX® platform; the status and timing of clinical studies, data analysis and communication of results; the potential benefits and mechanisms of action of product candidates; expectations for product candidates through development and commercialization; the timing of regulatory approval of product candidates; and projections of revenue, expenses and other financial items; the timing, manner and amount of capital deployment, including potential capital returns to stockholders; and risks related to the Company’s growth strategy. Other risks affecting Innoviva are described under the headings “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” contained in Innoviva’s Annual Report on Form 10-K for the year ended December 31, 2025 and Quarterly Reports on Form 10-Q, which are on file with the Securities and Exchange Commission (“SEC”) and available on the SEC’s website at www.sec.gov. Past performance is not necessarily indicative of future results. No forward-looking statements can be guaranteed, and actual results may differ materially from such statements. Given these uncertainties, you should not place undue reliance on these forward-looking statements. The information in this press release is provided only as of the date hereof, and Innoviva assumes no obligation to update its forward-looking statements on account of new information, future events or otherwise, except as required by law.
- 3 -
INNOVIVA, INC.
Condensed Consolidated Statements of Income
(in thousands, except per share data)
(Unaudited)
| Three Months Ended March 31, |
||||||||
| 2026 | 2025 | |||||||
| Revenue: |
||||||||
| Royalty revenue, net (1) |
$ | 55,167 | $ | 57,807 | ||||
| Net product sales |
41,371 | 30,279 | ||||||
| License and other revenue |
1,456 | 546 | ||||||
|
|
|
|
|
|||||
| Total revenue |
97,994 | 88,632 | ||||||
|
|
|
|
|
|||||
| Cost of products sold (inclusive of amortization of inventory fair value adjustments) |
15,607 | 8,842 | ||||||
| Amortization of acquired intangible assets |
6,554 | 6,475 | ||||||
|
|
|
|
|
|||||
| Gross profit |
75,833 | 73,315 | ||||||
|
|
|
|
|
|||||
| Operating expenses: |
||||||||
| Selling, general and administrative |
32,438 | 27,491 | ||||||
| Research and development |
5,241 | 4,396 | ||||||
|
|
|
|
|
|||||
| Total operating expenses |
37,679 | 31,887 | ||||||
|
|
|
|
|
|||||
| Income from operations |
38,154 | 41,428 | ||||||
| Changes in fair values of equity method investments, net |
157,650 | (13,549 | ) | |||||
| Changes in fair values of equity and long-term investments, net |
33,575 | (65,299 | ) | |||||
| Interest and dividend income |
10,987 | 4,538 | ||||||
| Interest expense |
(5,437 | ) | (4,711 | ) | ||||
| Other expense, net |
(366 | ) | (996 | ) | ||||
|
|
|
|
|
|||||
| Income (loss) before income taxes |
234,563 | (38,589 | ) | |||||
| Income tax expense |
(47,968 | ) | (7,995 | ) | ||||
|
|
|
|
|
|||||
| Net income (loss) |
$ | 186,595 | $ | (46,584 | ) | |||
|
|
|
|
|
|||||
| Net income (loss) per share: |
||||||||
| Basic |
$ | 2.52 | $ | (0.74 | ) | |||
| Diluted |
$ | 2.22 | $ | (0.74 | ) | |||
| Shares used to compute net income (loss) per share: |
||||||||
| Basic |
74,160 | 62,709 | ||||||
| Diluted |
84,849 | 62,709 | ||||||
| (1) | Total net revenue is comprised of the following (in thousands): |
| Three Months Ended March 31, |
||||||||
| 2026 | 2025 | |||||||
| (unaudited) | ||||||||
| Royalties |
$ | 58,623 | $ | 61,263 | ||||
| Amortization of capitalized fees |
(3,456 | ) | (3,456 | ) | ||||
|
|
|
|
|
|||||
| Royalty revenue, net |
$ | 55,167 | $ | 57,807 | ||||
|
|
|
|
|
|||||
- 4 -
INNOVIVA, INC.
Condensed Consolidated Balance Sheets
(in thousands)
(unaudited)
| March 31, | December 31, | |||||||
| 2026 | 2025 | |||||||
| Assets |
||||||||
| Cash and cash equivalents |
$ | 603,085 | $ | 550,941 | ||||
| Royalty and product sale receivables |
92,628 | 93,317 | ||||||
| Inventory |
38,843 | 39,172 | ||||||
| Prepaid expense and other current assets |
29,221 | 28,358 | ||||||
| Current portion of ISP Fund investments |
8,846 | 15,727 | ||||||
| Property and equipment, net |
2,142 | 1,555 | ||||||
| Equity method and equity and long-term investments |
764,454 | 598,223 | ||||||
| Capitalized fees |
52,682 | 56,138 | ||||||
| Right-of-use assets |
10,652 | 10,929 | ||||||
| Goodwill |
17,905 | 17,905 | ||||||
| Intangible assets |
175,602 | 182,156 | ||||||
| Other assets |
40,527 | 40,744 | ||||||
|
|
|
|
|
|||||
| Total assets |
$ | 1,836,587 | $ | 1,635,165 | ||||
|
|
|
|
|
|||||
| Liabilities and stockholders’ equity |
||||||||
| Other current liabilities |
$ | 32,650 | $ | 43,808 | ||||
| Accrued interest payable |
231 | 1,618 | ||||||
| Deferred revenue |
3,677 | 4,270 | ||||||
| Convertible senior notes, due 2028, net |
258,095 | 257,731 | ||||||
| Deferred tax liabilities, net |
72,831 | 31,793 | ||||||
| Income tax payable, long term |
58,345 | 57,013 | ||||||
| Other long term liabilities |
69,103 | 66,091 | ||||||
| Stockholders’ equity |
1,341,655 | 1,172,841 | ||||||
|
|
|
|
|
|||||
| Total liabilities and stockholders’ equity |
$ | 1,836,587 | $ | 1,635,165 | ||||
|
|
|
|
|
|||||
INNOVIVA, INC.
Cash Flows Summary
(in thousands)
(unaudited)
| Three Months Ended March 31, | ||||||||
| 2026 | 2025 | |||||||
| Net cash provided by operating activities |
$ | 35,282 | $ | 48,617 | ||||
| Net cash provided by (used in) investing activities |
37,008 | (34,674 | ) | |||||
| Net cash provided by (used in) financing activities |
(20,146 | ) | 183 | |||||
|
|
|
|
|
|||||
| Net change |
$ | 52,144 | $ | 14,126 | ||||
| Cash and cash equivalents at beginning of period |
550,941 | 304,964 | ||||||
|
|
|
|
|
|||||
| Cash and cash equivalents at end of period |
$ | 603,085 | $ | 319,090 | ||||
|
|
|
|
|
|||||
- 5 -
Contacts
Investor Relations (Internal):
Eleanor Barisser
Director, Investor Relations and Corporate Communications
Eleanor.barisser@inva.com
Investors and Media:
Argot Partners
(212) 600-1902
innoviva@argotpartners.com
- 6 -